List of Excipients in Branded Drug OZEMPIC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novo Nordisk	OZEMPIC	oral semaglutide	0169-1715	MAGNESIUM STEARATE	2033-03-15
Novo Nordisk	OZEMPIC	oral semaglutide	0169-1715	SALCAPROZATE SODIUM	2033-03-15
Novo Nordisk	OZEMPIC	semaglutide	0169-4136	PHENOL	2028-01-28
Novo Nordisk	OZEMPIC	semaglutide	0169-4136	PROPYLENE GLYCOL	2028-01-28

Ozempic Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

Ozempic is a semaglutide injectable supplied in a multidose prefilled pen. Its current formulation uses disodium phosphate dihydrate, propylene glycol, phenol, water for injection, and pH adjustment with hydrochloric acid or sodium hydroxide. The commercial opportunity is concentrated in peptide stabilization, multidose preservation, pen-device compatibility, alternative delivery systems, and manufacturing controls rather than in simple excipient substitution. Ozempic's scale, high prescription demand, and semaglutide patent barriers create a large market for formulation-enabling suppliers even before conventional generic entry becomes viable.

What excipients are used in Ozempic?

The FDA-approved Ozempic formulation contains the following excipients:

Component	Function in formulation
Disodium phosphate dihydrate	Buffering and pH control
Propylene glycol	Tonicity adjustment and formulation support
Phenol	Antimicrobial preservative for multidose use
Water for injection	Vehicle
Hydrochloric acid or sodium hydroxide	Final pH adjustment

Ozempic is a sterile semaglutide solution for subcutaneous administration. The product is supplied in prefilled multidose pens in 0.25 mg, 0.5 mg, 1 mg, and 2 mg dose presentations. The formulation is designed to support repeated needle access during the in-use period of the pen, making preservative effectiveness and container-closure compatibility commercially important (U.S. Food and Drug Administration [FDA], 2024a).

The formulation is not a conventional tablet excipient system. Semaglutide is a long-acting peptide with formulation risks that include aggregation, adsorption to surfaces, chemical degradation, subvisible particle formation, and sensitivity to temperature and mechanical stress.

How does the Ozempic excipient system support product performance?

The formulation performs four main functions.

Peptide stability

The phosphate buffer maintains the formulation within a controlled pH range. Peptide stability can be affected by pH-dependent hydrolysis, deamidation, oxidation, and conformational change. Buffer selection is therefore linked directly to potency, impurity growth, and particle control.

Multidose preservation

Phenol supports antimicrobial protection after repeated pen access. A preserved multidose product reduces the need for a new sterile container at every administration, which supports the pen-based commercial model.

Phenol concentration, preservative effectiveness, and preservative partitioning into the device or elastomer components require product-specific validation. A change in preservative system would typically trigger stability, extractables and leachables, container-closure, and antimicrobial-effectiveness work.

Tonicity and injection tolerability

Propylene glycol contributes to osmolality and may support solution properties. Subcutaneous injection products require control of osmolality, viscosity, pH, visible particles, and local tolerability.

Manufacturing robustness

Water for injection and pH adjustment agents appear simple, but commercial peptide production requires tight control of bioburden, endotoxin, particulate matter, and raw-material variability. Excipient suppliers that provide low-bioburden, low-endotoxin grades with strong global regulatory files have a competitive advantage.

What formulation patents protect Ozempic and semaglutide?

Ozempic is protected by a broader semaglutide intellectual-property estate that can include composition, use, formulation, manufacturing, and delivery-device claims. The relevant commercial barrier is not limited to the excipient list on the FDA label.

Protection category	Commercial relevance
Semaglutide composition	Protects the active peptide and related chemical subject matter
Diabetes treatment methods	Can restrict use of semaglutide products in type 2 diabetes
Cardiovascular-risk reduction methods	May affect labeling and launch strategy
Formulation claims	May cover concentration, stability, pH, excipient systems, or dosage forms
Pen-device claims	May cover dose delivery, cartridge configuration, or administration mechanics
Manufacturing claims	May affect peptide synthesis, purification, and scale-up
Trademark and regulatory exclusivity	Influences market access separately from patent scope

The FDA Orange Book identifies patents submitted by the sponsor for approved drug products. Patent status should be reviewed product by product because Ozempic, Wegovy, and Rybelsus may have overlapping semaglutide subject matter but different approved uses, dosage forms, and listing profiles (FDA, 2024b).

The practical implication for excipient companies is important: a formulation that uses different excipients may still infringe claims directed to the active ingredient, concentration, method of treatment, device, or manufacturing process.

When does Ozempic lose exclusivity?

Ozempic does not have one single loss-of-exclusivity date. Market access depends on several layers:

1. FDA regulatory exclusivity.
2. Listed patents in the Orange Book.
3. Pediatric exclusivity, if applicable.
4. Paragraph IV litigation and settlement terms.
5. The legal pathway selected by a competing developer.
6. Manufacturing readiness and FDA approval timing.

The core semaglutide patent estate has been widely reported as extending into the early 2030s in the United States, while individual patents can have different expiration dates. The relevant date for a competing product is the earliest legally available launch date after accounting for patent claims, litigation outcomes, pediatric extensions, and any settlement restrictions (Novo Nordisk, 2024; FDA, 2024b).

For excipient suppliers, this creates two market windows:

Period	Commercial opportunity
Before broad generic entry	Supply to Novo Nordisk, contract manufacturers, device vendors, and pipeline developers
Around patent challenge activity	Support alternative formulations, analytical comparability, and 505(b)(2) development
After first competitive approvals	Supply to multiple semaglutide manufacturers and differentiated delivery platforms
Post-launch	Cost reduction, second-source qualification, regional production, and lifecycle management

Are Paragraph IV challenges likely for Ozempic?

Paragraph IV challenges are likely to be relevant because semaglutide has high sales, strong demand, and a significant price differential between branded products and potential follow-on products. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or would not be infringed by the proposed product.

A challenger would need to address more than active-ingredient identity. Key issues could include:

• Peptide identity and purity.
• Reference-product formulation differences.
• Device and cartridge compatibility.
• Stability throughout the proposed shelf life.
• Preservative effectiveness in a multidose presentation.
• Dose accuracy across the pen lifecycle.
• Manufacturing and process-control comparability.
• Method-of-use patent exposure.
• Patent claims covering concentration or formulation parameters.

A formulation developer that avoids a listed formulation claim may still confront composition or method-of-use patents. Conversely, a formulation with a different excipient profile may reduce some formulation risk while creating new regulatory comparability requirements.

Is Ozempic exposed to biosimilar competition?

Ozempic is not normally analyzed through the FDA biosimilar pathway used for monoclonal antibodies and other biologics. Semaglutide is a peptide drug marketed through the drug approval framework, and competitive development is more likely to involve an ANDA, a 505(b)(2) application, or another drug-specific pathway than a conventional biosimilar application under the Public Health Service Act.

The pathway depends on FDA classification, reference-product designation, product sameness, delivery device, formulation differences, and the data required to support approval. A follow-on semaglutide product with a materially different excipient system or dosage form may need clinical bridging and additional safety data.

This distinction creates opportunities for:

• Peptide excipient platforms.
• Preservative-free presentations.
• Oral or buccal delivery systems.
• Long-acting depot formulations.
• Autoinjector and cartridge technologies.
• Analytical methods for peptide aggregation and particles.

What excipient strategies could improve on Ozempic?

Preservative-free single-dose presentations

A single-dose syringe, vial, or cartridge could eliminate phenol exposure and reduce preservative-related tolerability concerns. The tradeoff is higher packaging consumption, more complex logistics, and greater cost per administration.

Alternative buffer systems

Histidine, citrate, acetate, and other buffers could be evaluated for semaglutide stability and injection tolerability. Any alternative must control pH drift, peptide aggregation, particle formation, and interaction with device materials.

Surfactant or interface-control systems

Peptides can adsorb to glass, plastic, silicone oil, and elastomer surfaces. Low-level surfactants or alternative surface treatments may reduce interfacial stress. Such systems require close evaluation of oxidation, subvisible particles, and compatibility with the pen.

Reduced-viscosity formulations

Higher-concentration products can reduce injection volume but increase viscosity. A lower-viscosity formulation can support smaller-gauge needles, faster injection, or improved autoinjector performance. The commercial value depends on maintaining dose accuracy and stability.

Room-temperature stability

Expanded temperature tolerance would reduce cold-chain exposure and improve distribution in emerging markets. This is a high-value formulation target, but it requires real-time and accelerated stability data, shipping studies, and control of aggregation and potency loss.

Depot and extended-interval delivery

A depot formulation could reduce injection frequency. Potential approaches include biodegradable polymers, in situ gels, implants, or other controlled-release systems. These technologies introduce new risks involving burst release, local tolerability, dose recovery, extractables, and clinical pharmacokinetics.

Oral delivery

Rybelsus demonstrates that oral semaglutide is commercially feasible, but oral delivery requires a distinct formulation and dosing technology. Excipient opportunities include permeation enhancers, protective matrices, absorption promoters, and gastro-retentive systems. The oral product cannot be treated as a simple excipient replacement for Ozempic because exposure, food effects, and administration instructions differ.

What manufacturing and intellectual-property barriers affect excipient suppliers?

Excipient suppliers face qualification barriers even where the ingredients are commodity materials. Novo Nordisk and other large manufacturers typically require:

• Multiple validated manufacturing sites.
• Consistent compendial and noncompendial specifications.
• Low endotoxin and bioburden controls.
• Change-notification procedures.
• Extractables and leachables data.
• Global regulatory documentation.
• Supply continuity and inventory resilience.
• Compatibility data with peptide active ingredients and delivery devices.

The highest-value commercial position is often held by a supplier with a proprietary grade, a documented peptide-stabilization platform, or a formulation package that reduces development time. Commodity phosphate, phenol, propylene glycol, and water suppliers face pricing pressure unless they provide validated sterile or low-endotoxin grades.

Excipient-related patent claims can also create freedom-to-operate issues. A developer must review patents covering stabilizer combinations, concentration ranges, preservative systems, delivery devices, and controlled-release technologies.

Which companies are positioned to challenge Ozempic commercially?

Competitive pressure comes from several groups:

Competitor group	Products or capability	Risk to Ozempic
Novo Nordisk	Ozempic, Wegovy, Rybelsus	Lifecycle control across injectable and oral semaglutide
Eli Lilly	Mounjaro and Zepbound, tirzepatide	Direct incretin competition with strong efficacy and demand
Generic and follow-on developers	Potential semaglutide products	Price erosion after patent and regulatory barriers fall
Contract development manufacturers	Peptide synthesis, sterile fill-finish, pens	Enablement of competing products
Drug-delivery companies	Autoinjectors, cartridges, depot systems	Differentiation through convenience and dosing frequency
Excipient suppliers	Stabilizers, preservatives, surfactants, specialty grades	Improvement of stability, tolerability, and manufacturability

Mounjaro and Zepbound compete clinically and commercially but do not create direct semaglutide patent risk. Their presence can accelerate demand for improved delivery systems and increase pressure on injection-device cost and manufacturing capacity.

What is the FDA regulatory status of Ozempic?

Ozempic is FDA-approved for adults with type 2 diabetes as an adjunct to diet and exercise. The FDA label also includes reduction of the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (FDA, 2024a).

Ozempic is not the FDA obesity-labeled semaglutide product. Wegovy carries the chronic weight-management indication, while Rybelsus is the oral semaglutide product for type 2 diabetes. Different indications and dosage forms affect patent strategy, clinical requirements, promotional restrictions, and market segmentation.

Compounded semaglutide is not equivalent to FDA-approved Ozempic. FDA has reported concerns involving compounded semaglutide products, including dosing errors and use of semaglutide salt forms that may not be the same active ingredient as the approved drug (FDA, 2024c).

How strong is the Ozempic patent estate?

The estate is commercially strong because it combines a high-value peptide, multiple dosage forms, a large clinical market, proprietary delivery systems, and significant manufacturing complexity. Its strongest defenses are likely to involve active-ingredient and use claims, while formulation-only claims may be more vulnerable to design-around strategies.

Patent strength should be assessed across five dimensions:

1. Remaining term in each jurisdiction.
2. Claim breadth and validity history.
3. Ability to design around excipients and devices.
4. Availability of non-infringing therapeutic indications.
5. Manufacturing and supply-chain difficulty.

A formulation change can lower infringement exposure without creating a commercially viable product. The alternative must still match semaglutide exposure, stability, dose accuracy, patient usability, and regulatory requirements.

What is the revenue exposure associated with Ozempic?

Ozempic is one of Novo Nordisk's largest products. Novo Nordisk reported Ozempic sales of approximately DKK 95.7 billion in 2023, reflecting rapid growth in the GLP-1 market (Novo Nordisk, 2024). The product's commercial value extends beyond the Ozempic brand because semaglutide supports a broader franchise that includes Wegovy and Rybelsus.

This revenue base supports investment in:

• Higher-capacity peptide manufacturing.
• Second-source excipients.
• Pen and cartridge production.
• Cold-chain alternatives.
• Oral and long-acting delivery systems.
• Regional fill-finish capacity.
• Analytical testing for peptide purity and particles.

The most attractive excipient opportunities are tied to measurable product benefits: longer shelf life, higher concentration, lower injection volume, improved temperature stability, lower particle burden, reduced preservative exposure, or simplified manufacturing.

Key Takeaways

• Ozempic uses phosphate buffer, propylene glycol, phenol, water for injection, and pH adjustment agents.
• The central formulation challenge is stabilizing a peptide in a preserved multidose pen.
• Excipient substitution alone is unlikely to create a commercially viable follow-on product without device, stability, and regulatory work.
• High-value opportunities include preservative-free presentations, alternative buffers, interface-control excipients, concentrated formulations, room-temperature stability, depot delivery, and oral delivery.
• Ozempic's competitive barriers arise from patents, regulatory requirements, peptide manufacturing, pen technology, and supply-chain qualification.
• Semaglutide competition is more likely to use drug approval pathways such as ANDA or 505(b)(2) than a conventional biosimilar pathway.
• Patent and exclusivity analysis must be performed claim by claim and jurisdiction by jurisdiction.
• Revenue scale makes Ozempic an attractive target for excipient, device, contract manufacturing, and drug-delivery companies.

FAQs

Can phenol be replaced in an Ozempic follow-on formulation?

Yes, a developer could evaluate another preservative or a preservative-free single-dose presentation. The replacement would require antimicrobial-effectiveness, stability, compatibility, safety, and regulatory studies.

Which excipient is most important for semaglutide stability?

The buffer system is central to pH control, but stability also depends on container surfaces, temperature, concentration, preservatives, mechanical stress, and manufacturing conditions. No single excipient determines overall product stability.

Can a different excipient system avoid Ozempic patents?

Not necessarily. Semaglutide composition, treatment-method, device, manufacturing, and formulation claims may apply independently of the excipient list.

Is a compounded semaglutide product an Ozempic generic?

No. Compounded semaglutide is not an FDA-approved generic version of Ozempic. It does not establish therapeutic equivalence or substitute for an FDA-approved ANDA product.

What is the best commercial entry point for an excipient company?

Specialty grades with peptide-stability data, low endotoxin, global regulatory support, and documented compatibility with prefilled pens offer a stronger position than commodity supply alone.

References

1. U.S. Food and Drug Administration. (2024a). Ozempic prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024c). FDA’s concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/

4. Novo Nordisk A/S. (2024). Annual report 2023. https://www.novonordisk.com/investors/annual-report.html